United States: Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious. In so doing, the court rejected Purdue’s arguments that its discovery of the source of the toxic impurity that was minimized in the claimed products did not support patentability, because the solution to the problem did not depend on the source of the impurity.

The Perdue OxyContin Patents At Issue

There were four OxyContin® patents at issue, three of which claimed products having a low level of the toxic impurity referred to as “ABUKs” (α,β-unsaturated ketones) (U.S. Patent No. 7,674,799, U.S. Patent No. 7,674,800, and U.S. Patent No. 7,683,072), and one of which related to an abuse-resistant formulation (U.S. Patent No. 8,114,383). This article will focus on the court’s treatment of the “low-ABUK patents.”

According to the Federal Circuit decision, prior to the invention at issue oxycodone hydrochloride was made by a three-step process:

  • oxidizing thebaine to form 14-hydroxycodeinone (referred to in the decision as “14-hydroxy”)
  • converting 14-hydroxy to oxycodone free base by hydrogenation
  • reacting oxycodone free base with hydrochloric acid to form oxycodone hydrochloride

However, this process resulted in a final product with “high levels of 14- hydroxy, on the order of 1500 parts per million.” Since that compound was believed to be toxic, Purdue investigated how to make a product with lower levels of 14- hydroxy.

Its investigations led to the discovery that a particular isomer (8α, 14–dihydroxy–7,8– dihydrocodeinone ("8α")) was produced during the first step of the prior art process, and that the isomer was converted to 14-hydroxy during step three of the process. To solve this problem, Purdue added an additional hydrogenation step as a fourth step of the process, such that 14-hydroxy present after step three is converted to oxycodone free base in new step four.

Claim 1 of the ‘072 patent recites:

1. An oxycodone hydrochloride active pharmaceutical ingredient having less than 25 ppm 14-hydroxycodeinone, wherein at least a portion of the 14:hydroxycodeinone is derived from 8α,14-dihydroxy-7,8-dihydrocodeinone.

Claim 1 of the ‘799 patent recites:

1. An oral dosage form comprising particles, the particles comprising from about 5 mg to about 320 mg oxycodone hydrochloride active pharmaceutical ingredient having less than 25 ppm 14-hydroxycodeinone, wherein at least a portion of the 14-hydroxycodeinone is derived from 8α,14-dihydroxy-7,8-dihydrocodeinone during conversion of oxycodone free base to oxycodone hydrochloride, said particles being coated with an amount of hydrophobic material effective to provide a sustained release of the oxycodone hydrochloride when the coated particles are exposed to an aqueous solution.

Claim 30 of the ‘800 patent recites “Oxycodone salt prepared according to the process of claim 1,” where claim 1 recites:

1. A process for preparing an oxycodone salt substantially free of 14-hydroxycodeinone, which process comprises steps of: (a) preparing a mixture of oxycodone free base, solvent and an acid, the oxycodone free base having an 8α,14-dihydroxy-7,8-dihydrocodeinone component; (b) incubating the mixture under conditions suitable to convert the oxycodone free base to an oxycodone salt, wherein said conditions promote an acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone component to 14-hydroxycodeinone; and (c) preferentially removing the 14-hydroxycodeinone from the oxycodone salt.

The District Court Decision

Purdue commenced the district court litigation in response to Abbreviated New Drug Applications (ANDAs) filed by Amneal Pharmaceuticals, LLC, Epic Pharma, LLC, Mylan Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc. As summarized in the Federal Circuit decision, the district court found that all asserted claims were obvious on the grounds that “the prior art taught that oxidation of thebaine produced 14- hydroxy and that it was well known in the art that 14- hydroxy could be removed using hydrogenation.” The district court “determined that the discovery of 8α was not necessary to the claimed invention,” because “a skilled artisan would recognize that hydrogenation could be used to remove the remaining 14-hydroxy, regardless of the source of the 14-hydroxy.” The court also “concluded that the claim limitation requiring that the remaining 14-hydroxy is at least in part ‘derived from 8α[]’ is a product-by-process limitation and thus immaterial in the obviousness determination.”

The Federal Circuit Decision

The Federal Circuit decision was authored by Chief Judge Prost and joined by Judge Reyna and Chief District Judge Stark of the U.S. District Court for the District of Delaware, sitting by designation.

Chief Judge Prost noted that the parent application of the low-ABUK patents was before the court in 2009, when the court affirmed the USPTO Board’s rejection of the claims as obvious. Those claims were directed to the four-step manufacturing method, but “did not require that some of the remaining 14-hydroxy be derived from the 8α isomer.”

The Federal Circuit decision addresses three main Purdue arguments:

In response to Purdue’s argument that its “discovery of 8α as the core of the claimed inventions” should have been given more weight, the Federal Circuit distinguished the Supreme Court decision Purdue relied upon (Eibel Process Co. v. Minnesota & Ontario Paper Co., 261 U.S. 45 (1923)), because the “problem [of the source of the 14-hydroxy] did not need to be solved to arrive at the claimed invention.”

The issue again comes down to whether it would be obvious to a person having ordinary skill in the art to use hydrogenation to remove the excess 14-hydroxy in the oxycodone API. One need not know that the 14-hydroxy was derived from 8α as opposed to 8β to answer that question.

In response to Purdue’s argument that the requirement that “the remaining 14-hydroxy in the oxycodone API is derived from 8α” supports nonobviousness “because 8α was not previously known in the art as being the source of 14-hydroxy,” the Federal Circuit agreed with the district court that "because the clause at issue “does not describe the structure of 14-hydroxy” it “thus is a process limitation.” The Federal Circuit also noted that “the fact that the 14-hydroxy is derived from 8α imparts no structural or functional differences in the low-ABUK hydrocodone API as compared to the prior art products.”

In response to Purdue’s arguments of secondary considerations (the commercial success of Purdue’s API supplier, failure of others, praise by competitors), the Federal Circuit found no clear error in the district court’s findings of lack of nexus to the claimed invention or inadequate factual support.

The court therefore affirmed the district court decision holding the asserted claims of the low-ABUK patents to be invalid.

The Importance Of Product Claims

Purdue’s efforts to obtain a variety of product claims may reflect the importance of obtaining product claims to protect a pharmaceutical product. Patents that only claim a method of manufacturing a drug cannot be listed in the Orange Book, which means that would-be generic companies do not need to file Paragraph IV certifications against them with their ANDA applications. Method of manufacture claims also may be more susceptible to design-around options. For example, the Federal Circuit noted that Teva did not use the Purdue process to make its product. Still, method of manufacture claims can be valuable, particularly if they protect a commercially advantageous way to make the drug, or result in an improved product.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions